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Objective:  Neurofibromatosis type 2 (NF2), tuberous sclerosis (TS), and von Hippel-Lindau 
disease (VHL) are tumor suppressor syndromes characterized by multiple benign tumors of the 
peripheral and central nervous system.1  These tumors may lead to enhanced obstetric risk in 
female patients, but  it is currently unknown whether women with NF2, TSC, or VHL experience 
increased rates of adverse pregnancy outcomes.  Current data consists primarily of case series, 
even the largest of which may lack power due to small sample sizes.2-4         
 
Use of large administrative databases can facilitate studies of pregnancy in rare disorders, as 
shown by our prior work with neurofibromatosis 1, another neurogenetic tumor suppressor 
syndrome.  Using a population-based database, we found that pregnant women with NF1 
experienced increased maternal morbidity, including higher rates of hypertensive and 
cerebrovascular complications, than the general population.5  In the current study, we apply a 
similar methodology to determine the association between NF2, TS, and VHL and adverse 
pregnancy outcomes.  
 
Study Design:  We performed a retrospective cohort study using hospital discharge data from the 
US Nationwide Inpatient Sample, 1998-2008.  ICD-9-CM codes were used to identify 
pregnancy-related hospitalizations (codes 630-679) for women with NF2 (237.72), TS (759.5), 
or VHL (759.6).  Patients were compared to a control group of all pregnancy-related 
hospitalizations not associated with NF1, NF2, TS, or VHL in the same time period.  Admissions 
for women age <15 or >50 years were excluded in both groups.  ICD-9 codes were used to 
identify pre-eclampsia, ischemic and hemorrhagic cerebrovascular disease, pre-term labor, and 
caesarean delivery during hospitalization, as previously described.5  Multivariable logistic 
regression was used to investigate risk of adverse outcomes in each patient population, adjusting 
for age, pre-existing comorbidities, race, socioeconomic status, and hospital and insurance 
characteristics. Statistical analyses were performed using SAS version 9.1 (SAS Institute Inc., 
Cary, NC).  This study was approved by the Partners Institutional Review Board. 
 
Results:  Among 18,716,102 million pregnancy-associated admissions between 1988 and 2008, 
we identified 48 with maternal NF2, 112 with TS, and 135 with VHL.  Mean maternal age was 
25.5 years for TS, 26.6 years for NF2, 28.4 years for VHL, and 27.1 years for the control group.  
The majority of admissions for patients with tumor suppressor syndromes were at large urban 
teaching hospitals.  Patients with TS, but not NF2 or VHL, had higher rates of pre-existing 
hypertension than controls (12.5% vs. 4.0%).  Figure 1 presents the absolute rates, adjusted odds 
ratios (AOR) and 95% confidence intervals for adverse pregnancy outcomes.  Patients with NF2 
had significantly increased risk of pre-eclampsia (AOR, 3.5).  Patients with TS had significantly 
increased risk of pre-eclampsia (AOR, 2.8) and preterm labor (AOR, 2.1).   Patients with VHL 
had significantly increased risk of cerebrovascular disease (AOR, 12.5) and caesarean delivery 
(AOR, 1.8).  No patients with NF2, TS, or VHL died during their pregnancy-related 
hospitalizations. 
 
Conclusion:  Women with NF2, TS, and VHL may be at risk for certain adverse pregnancy 
outcomes.		Future research is needed to validate these findings, explore potential biological 
mechanisms for increased risk, and determine the impact of maternal morbidity on neonatal 
outcomes.	 	
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Figure 1 
 
Title: Multivariable odds of adverse outcomes by diagnostic category 
 
 
Legend:  Percentage of hospitalizations with an adverse outcome by diagnostic category and 
multivariate odds ratio of occurence comapred to unaffected population.  Shaded square 
represents point estimate for odds ration; lines represent 95% confidence interval. 
OR: Odds ratio; PTL: preterm labor; CVD: cerebrovascular disease. 
*Due to the small number of events for cerebrovascular disease in NF2 and TS, multivariable 
models were unreliable and thus an accurate odds ratio could not be determined.  
 †NIS policy prohibits reporting exact numbers or percentages in categories with less than 10 
events; for this reason, percentages are written as less than the equivalent of ten over the number 
of total hospitalizations in that diagnostic category 
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